**HPTN 084**

**Active Products**
- Long-acting injectable cabotegravir (CAB LA), oral cabotegravir (CAB), oral TDF/FTC

**Populations**
- About 3,200 cisgender women

**Locations**
- Botswana, Eswatini, Kenya, Malawi, South Africa, Uganda, Zimbabwe

**Study Design**
- Superiority of CAB LA to TDF/FTC
  - A superiority study tests whether one drug works better than another drug

**Study Steps**

**Arm A**
- Step 1: Two daily oral pills for 5 weeks – 1 active and 1 placebo
- Step 2: An injection every 8 weeks and a daily pill for up to 3.5 years
- Step 3: A daily oral pill for up to 1 year

**Arm B**
- Two daily oral pills for 5 weeks

**HPTN 084-01**

**Active Products**
- Long-acting injectable cabotegravir (CAB LA), oral cabotegravir (CAB), oral TDF/FTC

**Populations**
- About 50 cisgender female adolescents

**Locations**
- South Africa, Uganda, Zimbabwe

**Study Design**
- Safety, Tolerability and Acceptability of CAB LA
  - A safety study evaluates the safety of a drug and identifies its side effects

**Study Steps**

**Arm A**
- Step 1: A daily oral pill for 5 weeks
- Step 2: An injection every 8 weeks for 29 weeks
- Step 3: A daily oral pill for 48 weeks

**Arm B**
- Two daily oral pills for 5 weeks

= placebo